Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi

Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug saw their skin plaques ...